NEOS Investment Management LLC Takes Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

NEOS Investment Management LLC acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGTFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,936 shares of the technology company’s stock, valued at approximately $76,000.

Several other institutional investors have also recently made changes to their positions in the stock. Citigroup Inc. raised its holdings in shares of Cogent Biosciences by 3.2% during the third quarter. Citigroup Inc. now owns 82,241 shares of the technology company’s stock valued at $802,000 after purchasing an additional 2,522 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Cogent Biosciences by 15.2% in the 3rd quarter. Principal Financial Group Inc. now owns 21,267 shares of the technology company’s stock worth $207,000 after acquiring an additional 2,803 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Cogent Biosciences by 18.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 23,142 shares of the technology company’s stock worth $226,000 after acquiring an additional 3,570 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Cogent Biosciences by 42.9% in the 3rd quarter. Arizona State Retirement System now owns 15,446 shares of the technology company’s stock worth $151,000 after acquiring an additional 4,640 shares during the last quarter. Finally, PEAK6 Investments LLC raised its holdings in shares of Cogent Biosciences by 41.8% in the 3rd quarter. PEAK6 Investments LLC now owns 23,224 shares of the technology company’s stock worth $226,000 after acquiring an additional 6,844 shares during the last quarter.

Analyst Ratings Changes

COGT has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Cogent Biosciences in a report on Monday, May 13th. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Cogent Biosciences in a report on Wednesday, May 8th. Wedbush restated a “neutral” rating and issued a $10.00 target price on shares of Cogent Biosciences in a report on Friday, May 24th. JPMorgan Chase & Co. upped their price objective on shares of Cogent Biosciences from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Cogent Biosciences in a research report on Thursday, February 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cogent Biosciences presently has an average rating of “Moderate Buy” and an average target price of $14.67.

View Our Latest Stock Report on Cogent Biosciences

Cogent Biosciences Stock Down 0.2 %

Shares of COGT stock opened at $8.39 on Friday. Cogent Biosciences, Inc. has a 52-week low of $3.67 and a 52-week high of $13.50. The company has a 50-day simple moving average of $7.31 and a two-hundred day simple moving average of $6.62.

Cogent Biosciences (NASDAQ:COGTGet Free Report) last released its earnings results on Tuesday, May 7th. The technology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Equities research analysts predict that Cogent Biosciences, Inc. will post -2.19 earnings per share for the current year.

Cogent Biosciences Profile

(Free Report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Featured Articles

Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGTFree Report).

Institutional Ownership by Quarter for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.